ClinicalTrials.gg
CompletedNCT00396877CLARINETUpdated Oct 24, 2014Results posted

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

A Phase 3 interventional study of Clopidogrel (SR25990) and placebo in Heart Defects, Congenital, sponsored by Sanofi. Completed at 31 sites in 31 countries. Open to participants aged Up to 92 Days. Per ClinicalTrials.gov, last updated 2014-10-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
906
Allocation
Randomized
Ages
Up to 92 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 356 studies in Heart Defects, Congenital with a site in United States — 66 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Enrollment
4th of 184
906 · median 50
Started
2006
with 15 others
Phase 3
19 of 356
2 open now
Registered
44th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 4th largest by enrollment of the 184 interventional ones that give a count, is one of 16 that started in 2006, is one of 19 in phase 3, and was the 44th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

66 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.

This study: Up to 92 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.

The primary objective of the study is to evaluate the efficacy of Clopidogrel 0.2 mg/kg/day for the reduction of all cause mortality and shunt related morbidity in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt (e.g. modified Blalock Taussig Shunt [BTS]).

The secondary objective was to assess the safety of Clopidogrel in the study population.

Read the detailed description

In this event-driven study, participants were to be randomized and treated as soon as possible after shunt placement. They were then to be treated and followed until the primary endpoint criteria was reached i.e. (shunt thrombosis, the next surgical procedure for correction of the congenital heart disease or death) or one year of age or the common study-end-date, which ever came first.

The common study-en-date was defined as the date when it was projected that 172 participants would have reached the primary endpoint criteria.

03

Conditions studied

  • Heart Defects, Congenital

Keywords

  • cyanotic congenital heart disease
  • shunt palliation
  • thrombosis
  • clopidogrel
04

Who can participate

Ages eligible
Up to 92 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cyanotic congenital heart disease treated by any palliative systemic-to-pulmonary artery shunt.

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or increase risk of bleeding,
  • Allergy to 2 or more classes of drug,
  • Unable to receive drug orally or enterically,
  • Current or persistent thrombocytopenia, neutropenia, severe hepatic or renal failure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
906 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: placebo

  • Experimental
    Clopidogrel 0.2 mg/kg/day

    Drug: Clopidogrel (SR25990)

Interventions

  • Form: reconstituted solution using Clopidogrel powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight

    Also known as: Plavix

  • Drugplacebo

    Form: reconstituted solution using matching placebo powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight

06

What researchers measure

Primary outcomes

  1. Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)

    The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee. Only the first event was counted.

    Time frame: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)

Secondary outcomes

  1. Number of Participants With Bleeding Events

    Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.

    Time frame: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first

  2. Number of Participants According to Bleeding Type/Etiology

    For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.

    Time frame: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first

07

Results

Posted Mar 11, 2011

Participant flow

Recruitment was initially planned with a minimum of 490 participants anticipating that it would continue until a total of 172 participants reaching primary endpoint criteria is achieved. Finally 906 participants were enrolled and randomized between November 2006 and October 2009 in 134 sites in 31 countries. Actual median follow-up was 5.8 months.

Participant flow — Overall Study
MilestonePlaceboClopidogrel 0.2 mg/kg/Day
Started439467
Treated436464
Completed treatment356352
Completed433459
Not completed68
Withdrew: Lost to follow-up21
Withdrew: Parent(s)/guardian(s)'s request47

Outcome measures

PrimaryNumber of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)

The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee. Only the first event was counted.

Time frame:
Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)
Reported as:
Number · participants
Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)
participantsPlaceboClopidogrel 0.2 mg/kg/Day
Death / Shunt Thrombosis / Cardiac Procedure9089
- Death6051
- Shunt thrombosis2126
- Cardiac procedure <120 days of thrombotic nature912
Statistical analysis
  • Placebo vs Clopidogrel 0.2 mg/kg/Day · Log Rank · p = 0.4340 (The a-priori threshold for statistical significance was \< 0.035 reflecting the adjustment for interim analyses. No other adjustment for multiplicity was made.) · Relative risk reduction (%): 11.1 · 95% CI -19.2 to 33.6The Relative Risk Reduction (Clopidogrel versus placebo) and its corresponding 95% confidence interval were estimated using Cox's proportional hazards model.
SecondaryNumber of Participants With Bleeding Events

Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.

Time frame:
From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
Reported as:
Number · participants
Number of Participants With Bleeding Events
participantsPlaceboClopidogrel 0.2 mg/kg/Day
Any bleeding event8887
- Serious3230
- Serious with an outcome of death11
- Leading to permanent treatment discontinuation99
SecondaryNumber of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.

Time frame:
From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
Reported as:
Number · participants
Number of Participants According to Bleeding Type/Etiology
participantsPlaceboClopidogrel 0.2 mg/kg/Day
Spontaneous6056
Post-traumatic611
Puncture (vascular access site)199
Surgical1017

Adverse events

Collected over All Adverse Events (AE) regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—196/436 (45%)96/436 (22%)
Clopidogrel 0.2mg/kg/Day—234/464 (50.4%)107/464 (23.1%)
Most frequent serious events
Showing 10 of 298
Most frequent serious events
EventPlaceboClopidogrel 0.2mg/kg/Day
GASTROENTERITISInfections and infestations14/43624/464
CYANOSISCardiac disorders9/43624/464
PNEUMONIAInfections and infestations9/43621/464
BRONCHIOLITISInfections and infestations12/43615/464
HYPOXIARespiratory, thoracic and mediastinal disorders11/43614/464
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations13/43611/464
OXYGEN SATURATION DECREASEDInvestigations10/43611/464
SEPSISInfections and infestations4/4368/464
POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications4/4368/464
HAEMATOCHEZIAGastrointestinal disorders7/4362/464
Most frequent other events
Most frequent other events
EventPlaceboClopidogrel 0.2mg/kg/Day
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations53/43660/464
VOMITINGGastrointestinal disorders18/43632/464
NASOPHARYNGITISInfections and infestations24/43621/464
DIARRHOEAGastrointestinal disorders20/43624/464

Baseline characteristics

Age, Continuous
Age, Continuous(days)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Mean36.0 ± 22.536.1 ± 22.336.1 ± 22.4
Age, Customized
Age, Customized(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
≤ 30 days223238461
30 (<) - 92 days216229445
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Female185198383
Male254269523
Region of Enrollment
Region of Enrollment(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
United States9088178
Portugal101020
Taiwan121022
Hong Kong101
Thailand235
Spain161430
Israel347
Russian Federation131528
Italy201939
India202747
France111021
Malaysia549
Denmark336
South Africa131326
Netherlands246
China101121
Korea, Republic of325
Finland213
United Kingdom161632
Egypt4610
Hungary9918
Mexico323769
Canada5611
Argentina242852
Brazil313465
Belgium91221
Poland3710
Singapore224
Germany5459113
Norway8816
Sweden6511
Weight
Weight(kilograms (kg))PlaceboClopidogrel 0.2 mg/kg/DayTotal
Mean3.5 ± 0.73.4 ± 0.73.5 ± 0.7
Height
Height(Centimeters (cm))PlaceboClopidogrel 0.2 mg/kg/DayTotal
Mean51.8 ± 4.651.4 ± 4.451.6 ± 4.5
Type of systemic-to-pulmonary artery shunt palliation
Type of systemic-to-pulmonary artery shunt palliation(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Modified Blalock Taussig Shunt with Norwood5162113
Modified Blalock Taussig Shunt without Norwood252257509
Sano procedure with Norwood5460114
Sano procedure without Norwood257
Central shunt384078
Stent of ductus arteriosus424284
Not applicable011
Shunt on cardiopulmonary bypass
Shunt on cardiopulmonary bypass(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Yes177194371
No262273535

2 further baseline measures are reported on the registry.

08

Study locations

31 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 94609, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Shangaï, China
  • Sanofi-Aventis Administrative Office
    Horsholm, Denmark
  • Sanofi-Aventis Administrative Office
    Cairo, Egypt
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Causeway Bay, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Lysaker, Norway
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administraive Office
    Bangkok, Thailand
  • Sanofi-Aventis Admnistrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Wessel DL, Berger F, Li JS, Dahnert I, Rakhit A, Fontecave S, Newburger JW; CLARINET Investigators. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med. 2013 Jun 20;368(25):2377-84. doi: 10.1056/NEJMoa1114588. PubMed 23782178 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2006
First posted
Nov 8, 2006
Start
Nov 2006
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Mar 11, 2011
Last update
Oct 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396877
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 8, 2006
Start date
Nov 2006
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Mar 11, 2011
Last update
Oct 24, 2014

Study contacts

International Clinical Development Clinical Study Director
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion